ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1077

Cytomegalovirus Exposure in Nontransplant, Critically Ill CKD Patients

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Khullar, Dinesh, Max Super Speciality Hospital, Dehli, India
  • Sanjeevani, Scienthia, Max Super Speciality Hospital, Dehli, India
  • Grover, Rahul, Max Super Speciality Hospital, Dehli, India
  • Chhabra, Gagan, Max Super Speciality Hospital, Dehli, India
  • Bagai, Sahil, Max Super Speciality Hospital, Dehli, India
  • Singh, Prof Narinder Pal, Max Super Speciality Hospital, Dehli, India
  • Gupta, Anish Kumar, Max Super Speciality Hospital, Dehli, India

This study aimed to provide a comprehensive understanding of the incidence, and prevalence and to determine whether CMV infection had any significant impact on the clinical course and prognosis of non-transplant CKD patients in the intensive care unit setting.


A prospective study involved 94 patients with known cases of CKD stage 3 and above admitted to ICU due to acute illness or comorbidities. CKD Patients who had received corticosteroids, cytotoxic therapy, immunosuppressive medications, or had undergone solid organ or bone marrow transplantation were excluded. In our case, at the end of 3 weeks, the prevalence of CMV infection was defined as the percentage of patients who had the infection at that time, and incidence was defined as the percentage of patients who developed the infection at any point between the time of admission and 3 weeks. At 0, 1, and 3 weeks, a quantitative RT PCR analysis for CMV DNA was conducted. The primary outcome was to evaluate the incidence and prevalence of CMV infection. The secondary outcome was to assess the effect of CMV infection on patient outcomes, hospital stay, and 30-day mortality.


The prevalence of CMV infection was 9.57% with an incidence of 10.63 per 1000 patients. The mean age of CMV-infected patients was slightly higher (58.22± 8.829 vs 56.9 ± 7.638, p 0.148) compared to CMV non-infected. There was no significant difference in gender or the number of comorbidities between the two groups. The most common admitting diagnosis in both groups was sepsis (88.8% and 72.9%). The severity of the disease was higher in CMV-infected patients (p 0.044). CMV infection was associated with longer lengths of ICU stay but did not significantly impact hospital stay or 30-day mortality.


CMV infection is not uncommon among critically ill patients, irrespective of their immune status. It can occur in CKD patients even in the absence of overt immunodeficiency. The acquisition of CMV infection appears to be associated with the severity of illness in the ICU and is linked to higher morbidity. Such studies would provide valuable insights into the relationship between CKD and CMV, shedding light on associated risks and potential interventions.